EarningsQ4 2023 Earnings Report
DE:2EB0 Q4 2023 EPS Results
Actual EPS-€64.97
Consensus EPS-€72.32
Beat/MissBeat by +€7.34
One Year Ago EPS-€153.69
DE:2EB0 Q4 2023 Revenue Results
Actual Revenue€0.00
Expected Revenue€0.00
Beat/MissMet expectations
YoY Revenue Growth―
Earnings Announcement Details
QuarterQ4 2023
Date03/13/2024
TimeAfter Close
Conference CallWednesday, March 13, 2024
DE:2EB0 Upcoming Earnings
Quoin Pharmaceuticals's next earnings date is estimated for November 5, 2026, based on past reporting schedules.
Q4 2023 Earnings Call Audio
DE:2EB0 Q4 2023 Earnings Call
0:00 / 0:00
Q4 2023 Earnings Slide Deck
No slide deck is available for this earnings event.
Q4 2023 Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call reflects a generally positive outlook for Quoin Pharmaceuticals, with significant progress in clinical trials, strong commercial partnerships, and a solid financial position. However, challenges remain in managing cash burn and executing M&A strategies.Company Guidance
Transformational Year for Quoin
2023 was a transformational year for Quoin, marked by the release of the first-ever clinical data from a trial in Netherton syndrome subjects under an open IND with the FDA. The initial data was positive across several clinical endpoints with no safety signals.
Successful Protocol Amendments
The FDA cleared several protocol amendments, including increasing study sizes, changing dosing frequency, and lowering eligibility age to 14 years. These changes aim to generate more robust data sets and potentially expedite recruitment.
Strong Commercial Partnerships
Quoin has entered into 9 commercial partnerships covering 61 countries, which will facilitate a global launch of QRX003 once approved. This global network is unprecedented for a company of Quoin's size.
Positive Financial Position
Quoin completed a $6.5 million public offering, and entered an $8 million equity line of credit, extending the cash runway into the second half of 2026. The net loss decreased from $9.4 million in 2022 to $8.7 million in 2023.
DE:2EB0 Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed